TLDR: Variational AI, a key partner of Rakovina Therapeutics, has been awarded LifeSciencesBC’s 2025 Emerging Biotech Company of the Year. This recognition highlights the transformative impact of AI in drug discovery and validates the successful collaboration between the two companies in advancing next-generation cancer therapies, particularly the KT-5000 series.
VANCOUVER, British Columbia – Variational AI has been named LifeSciencesBC’s 2025 Emerging Company of the Year – Biotech, a prestigious accolade that underscores the growing influence of artificial intelligence in accelerating drug discovery. Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company focused on AI-powered cancer therapies, proudly congratulated its partner on this significant achievement.
The award recognizes British Columbia-based biotechnology companies demonstrating exceptional progress and strategic milestones. Variational AI’s innovative strides and momentum in the field have been particularly noted, especially its development of Enki™, the first commercially available foundation model for small-molecule drug discovery.
The partnership between Rakovina Therapeutics and Variational AI, established in September 2024, has been instrumental in leveraging Variational AI’s Enki™ generative AI platform to expedite the discovery of novel DNA damage response (DDR) kinase inhibitors. This collaboration has notably advanced the KT-5000 series, which represents the newest generation of synthetic small-molecule candidates targeting DDR pathways.
Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics, expressed his pride in the recognition, stating, “We’re proud to see Variational AI recognized as Emerging Biotech Company of the Year. This award highlights the transformative role of AI in drug discovery and reinforces the strength of our collaboration. Variational’s Enki™ platform has helped us identify novel drug candidates with remarkable speed and precision, and we look forward to advancing these promising therapies together.”
The collaboration has already yielded multiple structurally novel compounds exhibiting favorable drug-like properties and activity in validated cancer cell lines. Early data suggests these candidates hold strong promise as brain-penetrant agents, offering potential solutions for difficult-to-treat tumors and marking a significant leap forward in Rakovina Therapeutics’ AI-powered discovery pipeline.
Also Read:
- Redwood AI Pioneers AI-Driven Drug Synthesis, Earns BC Tech Awards Finalist Nod
- IQVIA Partners with NVIDIA to Launch Custom AI Agents for the Life Sciences Industry
Rakovina Therapeutics is dedicated to developing innovative cancer treatments through unique technologies targeting the DNA-damage response, powered by its proprietary Deep-Docking™ platform. By integrating AI, the company aims to significantly accelerate the review and optimization of drug candidates. Variational AI’s Enki™ platform further enhances this capability, enabling the rapid identification of promising compounds.
